Dr Keith Powell, Chairman of the Board
Dr Powell brings to Canbex his many decades of executive experience in biotechnology and pharmaceuticals in the UK and the US, gained at companies that range from start-ups to global firms. He worked for GSK and ICI, later Zeneca, in genetics and molecular biology and led several large groups including Discovery, finally running Zeneca's patent group. He then joined the West Coast biotech firm Maxygen, leading the small molecule group through the IPO and growing a business which was spun out as Codexis. On coming back to the UK, Dr Powell worked with the Bloomsbury Bioseed Fund (BBSF), an early investor in Canbex, and acted as CEO for several of the companies in the BBSF portfolio, including Spear, which was sold to Advent International. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry. Under his guidance, drug delivery start-up Polytherics was grown organically to a company of over thirty people. Dr Powell is currently chairman of Domainex and Biomoti as well as Canbex.